原创力文档adjuvant therapy for locally advanced renal cell cancer a systematic review with meta-analysis辅助治疗局部晚期肾细胞癌的系统回顾和荟萃分析.pdfVIP
- 1、原创力文档（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。。
- 2、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击 这里二次下载。
- 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。
- 4、该文档为VIP文档，如果想要下载，成为VIP会员后，下载免费。
- 5、成为VIP后，下载本文档将扣除1次下载权益。下载后，不支持退款、换文档。如有疑问请联系我们。
- 6、成为VIP后，您将拥有八大权益，权益包括：VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
- 7、VIP文档为合作方或网友上传，每下载1次， 网站将根据用户上传文档的质量评分、类型等，对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
adjuvant therapy for locally advanced renal cell cancer a systematic review with meta-analysis辅助治疗局部晚期肾细胞癌的系统回顾和荟萃分析
Scherr et al. BMC Cancer 2011, 11:115
/1471-2407/11/115
RESEARCH ARTICLE Open Access
Adjuvant therapy for locally advanced renal cell
cancer: A systematic review with meta-analysis
*
Adolfo JO Scherr, Joao Paulo SN Lima, Emma C Sasse, Carmen SP Lima and André D Sasse
Abstract
Background: Many adjuvant trials have been undertaken in an attempt to reduce the risk of recurrence among
patients who undergo surgical resection for locally advanced renal cancer. However, no clear benefit has been
identified to date. This systematic review was conducted to examine the exact role of adjuvant therapy in renal
cancer setting.
Methods: Randomized controlled trials were searched comparing adjuvant therapy (chemotherapy, vaccine,
immunotherapy, biochemotherapy) versus no active treatment after surgery among renal cell cancer patients.
Outcomes were overall survival (OS), disease-free survival (DFS), and severe toxicities. Risk ratios (RR), hazard ratios
(HR) and 95% confidence intervals were calculated using a fixed-effects meta-analysis. Heterogeneity was measured
by I2. Different strategies of adjuvant treatment were evaluated separately.
Results: Ten studies (2,609 patients) were included. Adjuvant therapy provided no benefits in terms of OS (HR 1.07;
95%CI 0.89 to 1.28; P = 0.48 I2 = 0%) or DFS (HR 1.03; 95%CI 0.87 to 1.21; P = 0.77 I2 = 15%) when compared to no
treatment. No subgroup analysis (immunotherapy, vaccines, biochemotherapy and hormone therapy) had relevant
results. Toxicity evaluation depicted a significantly higher frequency of serious adverse events in the adjuvant
group.
Conclusions: This analysis provided no support for the hypothesis that the agents studied provide any clinical
benefit
您可能关注的文档
- accurate multiple sequence-structure alignment of rna sequences using combinatorial optimization准确使用组合优化rna序列的多个序列结构对齐.pdf
- acetaminophen-cysteine adducts during therapeutic dosing and following overdoseacetaminophen-cysteine加合物在治疗剂量和过量.pdf
- accurate prediction of protein secondary structure and solvent accessibility by consensus combiners of sequence and structure information准确预测蛋白质二级结构和溶剂可及性的共识序列和结构信息的组合器.pdf
- acetic acid-indigo carmine chromoendoscopy for delineating early gastric cancers its usefulness according to histological type醋酸acid-indigo胭脂chromoendoscopy描述早期胃癌症根据组织学类型它的实用性.pdf
- acetoacetate reduces growth and atp concentration in cancer cell lines which over-express uncoupling protein 2乙酰乙酸盐可以减少癌症细胞系的生长和atp浓度过解偶联蛋白2.pdf
- acetylation of p65 at lysine 314 is important for late nf-κb-dependent gene expression在赖氨酸乙酰化的p65 314对于nf-κb-dependent晚期基因表达是很重要的.pdf
- acetylation of insulin receptor substrate-1 is permissive for tyrosine phosphorylation乙酰化作用的胰岛素受体底物对酪氨酸磷酸化是宽容的.pdf
- ace (id) polymorphism and response to treatment in coronary artery disease a comprehensive database and meta-analysis involving study quality evaluationace(id)多态性和对治疗的反应在冠状动脉疾病涉及研究质量评价的综合数据库和荟萃分析.pdf
- acetylcholinesterase alterations reveal the fitness cost of mutations conferring insecticide resistance乙酰胆碱酯酶的变化揭示杀虫剂耐药性相关的变异的健康成本.pdf
- acetylcholinesterase assay for cerebrospinal fluid using bupivacaine to inhibit butyrylcholinesterase乙酰胆碱酯酶测定脑脊液使用bupivacaine抑制butyrylcholinesterase.pdf
- adjuvant chemotherapy of pt1a and pt1b breast carcinoma results from the nemesi study辅助化疗pt1a和pt1b乳腺癌nemesi研究的结果.pdf
- adjuvant treatment of her2-positive breast cancer winning efforts continue to improve her2-positive patient outcome long-termher2阳性乳腺癌的辅助治疗赢得努力继续提高her2阳性病人的长期结果.pdf
- admission to hospital following head injury in england incidence and socio-economic associations进入医院后头部受伤在英格兰发病率和社会经济关联.pdf
- adjuvant treatment the contribution of expression microarrays辅助治疗的贡献表达微阵列.pdf
- adenomyoepithelial tumours and myoepithelial carcinomas of the breast – a spectrum of monophasic and biphasic tumours dominated by immature myoepithelial cellsadenomyoepithelial肿瘤和乳腺肌上皮癌u2014u2014频谱的单相和两相的肿瘤由不成熟的肌上皮细胞.pdf
- adjuvant glycerol is not beneficial in experimental pneumococcal meningitis辅助甘油不是有益的实验肺炎球菌脑膜炎.pdf
- adolescent diet and risk of breast cancer青少年饮食和乳腺癌的风险.pdf
- adjuvant trastuzumab in the treatment of her-2-positive early breast cancer a meta-analysis of published randomized trials辅助曲妥珠单抗治疗her-2-positive早期乳腺癌发表的随机试验的荟萃分析.pdf
- adolescents perception of reproductive health care services in sri lanka青少年生殖健康保健服务在斯里兰卡的看法.pdf
- admission of advanced lung cancer patients to intensive care unit a retrospective study of 76 patients入学的晚期肺癌患者重症监护病房76名患者的回顾性研究.pdf
文档评论（0）